

# CMI Implant for Anytime/Immediate Loading

台灣 紐白特

李在熙

# Overview

# CMI Implant Solutions for Anytime(Immediate) loading+

+IS-II active overview

+IS-III active overview

+Difference of IS-II active & IS-III active

+Product concept of IS-II active & IS-III active

+IS-III active S-narrow

+Clinical literature



## +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature

## IS-II active overview (Released in 2011)



BioSeal (0.5mm) Increase sealing of soft tissue and minimize bone loss



S.L.A. Surface Under 50 mm Hydroxy Apatite powder blasting and dual acid etching



Apex Excellent for both immediate placement and immediate loading




Coronal Macro Thread (Thread pitch 0.8mm) Excellent primary stability at cortical bone



Magic Thread Specially designed to endure vertical and lateral force















# IS-III active overview (Released in 2016)

- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature





+IS-II active overview

+IS-III active overview

+Difference of IS-II

active & IS-III active

+Product concept of

+IS-III active S-narrow

IS-II active & IS-III


+Clinical literature


active

# Difference of IS-II active & IS-III active (Overview)

Meo Biotech Satisfaction to Dentists

IS-II Active IS-III Active







- +IS-III active overview

+IS-II active overview


- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III

active

- +IS-III active S-narrow
- +Clinical literature



## **Product Concept of IS-II active & IS-III active**






## **Product Concept of IS-II active & IS-III active (Wall Thickness)**


- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III


#### active

- +IS-III active S-narrow
- +Clinical literature
























Ø5.0

Ø3.35

## **Product Concept of IS-III active (Wall Thickness)**

Ø3.5

Ø3.19


0.255

Ø4.0


Ø3.25

## **IS-III** active





Implant system	Manufacturer	Taper angle (degrees)	Diameter (mm)	Inner connecting dimension (mm)	Thinnest wall thickness (mm)
Astra Tech OsseoSpeed TX	Dentsply	11	4.0 <sup>a</sup> 4.5	3.5 3.5	0.22 0.32
NobelActive	Nobel Biocare	12	4.3	3.4	0.45
NobelReplaceConical Connection			4.3	3.4	0.49
Bone Level RC Implant	Straumann	15	4.1	3.3	0.44
TS III	Osstem	11	4.2 4.4	3.35 3.35	0.28 0.44
Implantium	Dentium	11	4.0 4.5	3.35 3.35	0.35 0.53



Ø4.5

Ø3.25

0.425

0.375

Effect of the Coronal Wall Thickness of Dental Implants on the Screw Joint Stability in the Internal Implant-Abutment Connection September 2016, The International journal of oral & maxillofacial implants 31(5):1058-1065 DOI:10.11607/jomi.4600

<sup>\*</sup> Product dimension on before 2008



# Product Concept of IS-II active & IS-III active (Body design)

- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature








IS-II active has better penetration.


IS-III active

Stuck!!!

## **IS-III** active







IS-III active has a shallow depth of thread in about 1/3 of the upper part of fixture

IS-II active

Tapping is a must in Hard Bone Case



- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III

#### active


- +IS-III active S-narrow
- +Clinical literature

# **Product Concept of IS-II active & IS-III active (Cutting Edge)**




#### **IS-II** active





**IS-III** active







**IS-II** active

**IS-III** active

IS-III active improves self-tapping capability



# +IS-III active overview

- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III

active


+IS-III active S-narrow

## Product Concept of IS-II active & IS-III active (Apex Design)




## **IS-II** active






Narrow Apex is useful for sinus

**IS-III** active









Apex	Ø3.5	Ø4	Ø4.5	Ø5
IS-II (Narrow)	2	2.4	2.9	3.4
IS-III	2.4	2.8	3.2	3.7


- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature

## **IS-III** active S-narrow

Super Narrow for Anterior Mandible (Narrow Ridge)



#### **Fixture**



Diameter	Length	Code
	8.5 mm	IS3SN3008AP
	10.0 mm	IS3SN3010AP
Ø3.2	11.5 mm	IS3SN3011AP
	13.0 mm	IS3SN3013AP

\* Cover Screw not included

#### Cover Screw



100	J
Diameter	Code
Ø3.0	ISC25S

#### Healing Abutment



Diameter	Ø	3.0	
Cuff	3 mm	5 mm	
Code	ISH3003	ISH3005	



Diameter	Ø	3.8
Cuff	3 mm	5 mm
Code	ISH3803	ISH3805

- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



## **IS-III** active S-narrow





#### S.L.A. Surface

The new S.L.A Surface with 40% greater sur-face area and 50% more cell adhesion promotes osseointegration



#### Straight Body

Easy to adjust implantation depth



#### Deep & Wide Pitch

Optimum Pitch for osseointegration (0.9Pitch)



#### Wide Cutting Edge


Wide cutting edge and enlarged surface area enhances initial fixation and offers clinicians more stable implant placement




# Difference of IS-III active S-narrow & IS-II/IS-III active



- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature





IS-II active & IS-III active (Ø3.5/Ø4.0/Ø4.5/Ø5.0)

**IS Connection** 

A: 11° Conical Seal

B: 2.5 Hex

Screw: M2.0

- +IS-II active overview
- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature

## **IS-III** active clinical paper







rticle

One-Year Results of a Randomized Controlled Clinical Trial of Immediately Loaded Short Implants Placed in the Lower Posterior Single Molar Using a Complete Digital Workflow

Yeon-Wha Baek  $^1$ , Young-Jun Lim $^{1,+}@$ , Jungwon Lee $^2@$ , Ki-Tae Koo $^3$ , Myung-Joo Kim $^1@$  and Ho-Beom Kwon  $^1$ 

- Department of Prosthodontics and Dental Research Institute, School of Dentistry, Seoul National University, Seoul 03080, Korea; notus@hanmail.net (Y.-W.B.); silk1@snu.ac.kr (M.-J.K.); proskwon@snu.ac.kr (H.-B.K.)
- Department of Periodontics, One-Stop Specialty Center, Seoul National University, Dental Hospital, Seoul 03080, Korea; jungwonlee.snudh@gmail.com
- 3 Department of Periodontology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul 03080, Korea: periokoo@snu.ac.kr
- Correspondence: limdds@snu.ac.kr; Tel.: +82-2-2072-2940

Correspondence: iimdds@snu.ac.kr; iei.: +82-2-20/2-2940

Received: 5 January 2019; Accepted: 22 March 2019; Published: 27 March 2019



Abstract: The purpose of this randomized clinical trial is to evaluate immediately loaded single implants with varying lengths in the posterior mandible using a fully digital, model-free prosthetic-driven implant planning pathway, and to compare clinical and radiological outcomes of short and long implants. The 52 patients with the single tooth missing in the posterior molar regions of the mandible were randomly assigned to the control (CMI IS-III active® long implant; 5.0 × 10 mm) and experimental (CMI IS-III active® short implant; 5.5 × 6.6, 7.3, 8.5 mm) groups. For each patient, a single implant was placed using the computer aided surgical template and all prostheses were fabricated by means of computer-aided design/computer-aided manufacturing (CAD/CAM) system on the virtual model. The patients received provisional and definitive monolithic zirconia prostheses at 1 week and 12 weeks after implant surgery, respectively. The implant stability quotient (ISQ) measurements and periapical radiographs were taken and peri-implant parameters were evaluated at 1, 3, 4, 8, 12, 24, 36, and 48 weeks after surgery. Nineteen long implants and 27 short implants were finally used for the statistical analysis. There was no significant difference between the groups in terms of insertion torque, ISQ values (except 3 weeks), marginal bone loss, and peri-implant soft tissue parameters (p > 0.05). Both groups exhibited no stability dip during the early phase of healing. The average marginal bone loss from the baseline of implant placement for the control and experimental groups was -0.07 and 0.03 mm after 12 weeks and 0.06 and 0.05 mm after 48 weeks. All of the soft tissue parameters were within normal limits. Within the limits of the short term follow up, immediate loading of short single implants can be considered as one of predictable treatment modality in mandible with reduced bone height when primary stability can be achieved.

Keywords: dental implants; short dental implants; immediate loading; primary stability; digital work flow

#### 1. Introduction

Due to advancements in 3-dimensional (3D) imaging and computer-aided design/computer-aided manufacturing (CAD/CAM) technology, clinicians can not only obtain required diagnostic information in a single visit, but also complete the entire process from implant surgery to the definitive prosthesis

Appl. Sci. 2019, 9, 1282; doi:10.3390/app9071282

www.mdpi.com/journal/applsci

Appl. Sci. 2019, 9, 1282

Another outcome variable included peri-implant soft tissue assessment such as probing depths, width of keratinized mucosa and plaque and calculus indices.



Figure 1. Characteristics of the implants systems used in this study: CMI IS-III active® (Neobiotech, Seoul, Korea),

#### 2.2. Study Population and Entry Criteria

The required sample size was estimated based on the non-inferiority test using Chi-squared formulas:

$$N = \frac{\left\{Z_{\alpha}\left[\left(1+\lambda\right)P^{2}\left(1-P^{2}\right)\right]^{0.5} + Z_{\beta}[\lambda P_{c}(1-P_{c}) + Pt\left(1-Pt\right)]^{0.5}\right\}^{2}}{\lambda\left(P_{c} - P_{f} - d\right)} = 18.133 = 19 \text{ subject,}$$

where  $Z_{cs}=5\%$ ,  $Z_{pl}=20\%$ ,  $\lambda=1$ ,  $P^{n}=P_{t}=0.968$ ,  $P_{c}=0.971$ , and d=0.145. A dropout rate of 30% was assumed. Since each subject received one implant, the number of participants required for each group was approximately 26.

Å total of 108 potential participants were recruited via a subway car advertising. The study population was derived from participants under treatment at Seoul National University Dental Hospital between April 2016 and July 2018. Fifty-six of a total of 108 screened candidates were excluded by the entry criteria. A total of fifty-two patients were randemly assigned to one of the control (CMI IS-III active<sup>8</sup> long implant) and the experimental (CMI IS-III active<sup>8</sup> short implant) groups, using a computerized random number generator. The inclusion criteria were: (1) 18 years of age or older, (2) single tooth missing in the posterior modar regions of the mandible at least 3 months ago, (3) ability of patient to undergo surgical and restorative procedures, (4) sufficient bone rolume in the site to allow implant placement without the need for bone augmentation: at least 8.0 mm diameter and 9.0 mm length, (5) the presence of the intact occlusal plane opposed with the edentitious surgical site, and (6) a lack of TMD (Temporomandibutal risorders) or any other

Appl. Sci. 2019, 9, 1282 9 of 16


Table 2. Comparison of primary stability between the long and short implants.

	Control Neobiotech CMI IS-III Active® Long Implant	Experimental Neobiotech CMI IS-III Active® Short Implant	
Participant number	19	27	p-value*
Insertion Torque (Ncm) (Mean ± SD)	$40.53 \pm 5.35$	$38.89 \pm 4.85$	0.298

 $78.69 \pm 5.08$ 

0.120

\* The p-values for insertion torque and ISQ were calculated by the t-test ISO, implant stability quotient: SD, standard deviation.



	Number	Surgery	1- week	3- week	4- week	8- week	12- week	24- week	36- week	48- week
Control		81.53	82.49	84.34	83.74	87.51	88.46	89.98	90.75	90.76
long Implant	19	±	1	2	2	2	#	1	2	2
(Mean ± SD)		6.26	5.14	5.57	5.21	2.29	1.62	2.67	1.47	2.09
Experimental		78.69	80.99	80.33	80.83	85.46	87.82	89.99	89.39	91.51
short Implant	27	*	1		±		±	±	2	*
(Mean ± SD)		5.08	5.17	5.16	5.54	4.80	3.38	2.46	3.07	1.79
P-value* between implant groups		0.105	0.348	0.018	0.087	0.098	0.454	0.994	0.086	0.207
Within-subjects effects (visits)			p	< 0.01 (F	łuynh-Fe	eldt, Sph	ericity A	ssumed)		
Within-subjects effects(visits & implant groups)			P	= 0.074 (	Huynh-F	eldt, Spl	sericity A	Assumed	)	

\* The P-values were calculated using the two-way repeated measures ANOVA.

Q. implant stability quotient; SD, standard deviation.

Figure 6. Comparison of stability in terms of the pattern of change in implant stability quotient (ISQ) during the 48-week observation period after implant surgery.

#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



## **IS-III** active clinical paper





Article

# One-Year Results of a Randomized Controlled Clinical Trial of Immediately Loaded Short Implants Placed in the Lower Posterior Single Molar Using a Complete Digital Workflow

Yeon-Wha Baek <sup>1</sup>, Young-Jun Lim <sup>1,\*</sup>, Jungwon Lee <sup>2</sup>, Ki-Tae Koo <sup>3</sup>, Myung-Joo Kim <sup>1</sup>
and Ho-Beom Kwon <sup>1</sup>

- Department of Prosthodontics and Dental Research Institute, School of Dentistry, Seoul National University, Seoul 03080, Korea; notus@hanmail.net (Y.-W.B.); silk1@snu.ac.kr (M.-J.K.); proskwon@snu.ac.kr (H.-B.K.)
- Department of Periodontics, One-Stop Specialty Center, Seoul National University, Dental Hospital, Seoul 03080, Korea; jungwonlee.snudh@gmail.com
- Department of Periodontology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul 03080, Korea; periokoo@snu.ac.kr




#### +IS-II active overview


- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



## **IS-III** active clinical paper

• 52 patients with the single tooth missing in the posterior molar regions of the mandible (6 participants excluded due to Consent withdrawal :1, Exclusion criteria 5)









**Experimental Group** 


#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



## **Clinical Study Design**

- CMI IS-III active® long implant (Neobiotech Co., Seoul, Korea) in the control group
- CMI IS-III active® short implant (Neobiotech Co., Seoul, Korea) in the experimental group




#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature

## **Treatment Procedure**

- Planning: Implant Studio(3shape)
- Surgical guide : Neo Navi Guide
- Customized Prosthesis: DentalDesigner (3shape)








#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



#### **Treatment Procedure**

evaluation of peri-implant soft tissue parameters



 Flow diagram of the controlled clinical trial protocol used in this study.

#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



## Measurement of Marginal Bone Loss

- Peri-Implant marginal bone loss (PIMBL) was evaluated using standard periapical radiographs
  taken immediately after surgery and at 12 and 48 weeks after the implant installation
  (Figures 4 and 5).
- In order to obtain the marginal bone level, the enlargement ratio of each image was
  calculated from the manufacturer-specified thread pitch of 0.9 mm that is known for each
  implant system used in this study




Figure 4. Standard periapical radiographs of implants placed in a patient in the control group (CMI IS-III active<sup>®</sup> long implant, Neobiotech Co., Seoul, Korea): (a) at surgery, (b) at 12 weeks, and (c) at 48 weeks.




Figure 5. Standard periapical radiographs of implants placed in a patient in the experimental group (CMI IS-III active® short implant, Neobiotech Co., Seoul, Korea): (a) at surgery, (b) at 12 weeks, and (c) at 48 weeks.

#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



#### Result

The statistical analysis showed that there were **no significant differences** in age, sex, implant type, and bone quality between the two groups (p > 0.05).

	Variables	Control (Neobiotech CMI IS-III Active <sup>®</sup> Long Implant)	Experimental (Neobiotech CMI IS-III Active® Short Implant)	<i>p</i> -Value
	Participant number	19	27	0.514
	Age (mean $\pm$ SD)	$55.42 \pm 11.75$	$52.06 \pm 11.05$	0.305
Participant based	20–60	13	18	0.740
(n = 46)	Over 60	6	9	
	Sex			
	Male /Female	15/4	19/8	0.514
	Implant number	19	27	
	Lower 1st molar / 2nd molar Implant Type	9/10	4/23	
	Ø5.00 × 10 mm	19	/	
	$\emptyset$ 5.50 × 8.5 mm	/	10	1.000
	$\emptyset$ 5.50 × 7.3 mm	/	9	
	$\emptyset$ 5.00 × 6.6 mm	/	8	
Implant based	Bone quality			
(n = 46)	D112	0	4	
	D122	3	3	
	D211	0	1	
	D222	6	7	0.378
	D223	1	1	
	D232	0	1	
	D233	3	7	
	D333	6	3	

#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature




## **Result (Comparison of Implant Stability)**

Table 2. Comparison of primary stability between the long and short implants.

	Control Neobiotech CMI IS-III Active <sup>®</sup> Long Implant	Experimental Neobiotech CMI IS-III Active <sup>®</sup> Short Implant	
Participant number	19	27	p-value *
Insertion Torque (Ncm) (Mean ± SD)	$40.53\pm5.35$	$38.89 \pm 4.85$	0.298
ISQ at surgery (Mean $\pm$ SD)	$81.53 \pm 6.26$	$78.69 \pm 5.08$	0.120

<sup>\*</sup> The *p*-values for insertion torque and ISQ were calculated by the t-test. ISQ, implant stability quotient; SD, standard deviation.



- Primary stability was evaluated using the peak insertion torque and ISQ at surgery (Table 2).
- The control group had slightly greater average insertion torque and ISQ values at implant insertion than the experimental group, but no statistically significant differences were observed between the long and short implants (p-value > 0.05).

#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III

active

+Clinical literature

+IS-III active S-narrow



## Result (Comparison of Marginal Bone Loss)

- The average marginal bone loss from the fixture platform top for the control and experimental groups was  $-0.07 \pm 0.78$  mm and  $0.03 \pm 0.63$  mm after 12 weeks and  $0.06 \pm 0.82$  mm and  $0.05 \pm 0.77$  mm after 48 weeks, respectively.
- After a 12-week healing period, the distal surface exhibited slightly greater bone loss than the mesial side, but by the end
  of the trial, no differences in marginal bone loss between the two implant groups gained statistical significance (p-value >
  0.05)

Table 3. Comparison of marginal bone loss between the long and short implants.

		Control Neobiotech CMI IS-III Active® Long Implant	Experimental Neobiotech CMI IS-III Active® Short Implant	
Participant nun	nber	19	27	
Duration	Area	Mean ± SD (mm)	Mean ± SD (mm)	p-value *
12-week follow up	Mesial	$-0.22 \pm 0.98$	$-0.15 \pm 0.79$	0.893
353	Distal	$0.08 \pm 0.81$	$0.20 \pm 0.78$	0.728
	Avg.	$-0.07 \pm 0.78$	$0.03 \pm 0.63$	0.885
48-week follow up	Mesial	$-0.15 \pm 0.94$	$-0.13 \pm 0.82$	0.719
1.5	Distal	$0.27 \pm 0.80$	$0.23 \pm 0.92$	0.573
	Avg.	$0.06 \pm 0.82$	$0.05 \pm 0.77$	0.655

<sup>\*</sup> The p-values were calculated using the Mann-Whitney test.

Normality test was failed (Shapiro-Wilk, p < 0.05).

Area, the radiographic measurement area for calculation of marginal bone loss; Avg., the average value of mesial and distal bone loss; SD, standard deviation.



#### +IS-II active overview

- +IS-III active overview
- +Difference of IS-II
- active & IS-III active
- +Product concept of
- IS-II active & IS-III
- active
- +IS-III active S-narrow
- +Clinical literature



## Conclusion

- The present study was performed with immediate loading protocol and used the completely digital pathway, short and standard-length implants supporting single prosthesis in the posterior mandible, showed no significant differences in terms of success rate, ISQ values, marginal bone loss, and peri-implant soft tissue parameters during the 1-year follow up period.
- Within the limitations of this study, the short implant supporting single crown with immediate loading protocol seems
  to be a successful treatment modality in the limited bone height mandible as long as adequate primary stability can be
  achieved; insertion torque of 35–45 Ncm and ISQ of more than 65. To consolidate this alternative solution for reduced
  bone, however, additional randomized controlled trials with larger sample sizes and longer follow-up periods are
  required.

